BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 25-Apr-2017

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2017 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2017.

SQURPHARMA 29-Jan-2017

(Q2 Un-audited): Consolidated EPS was Tk. 3.58 for October-December, 2016 as against Tk. 3.21 for October-December, 2015; Consolidated EPS was Tk. 7.11 for July-December, 2016 as against Tk. 6.10 for July-December, 2015. Consolidated NOCFPS was Tk. 8.54 for July-December, 2016 as against Tk. 8.93 for July-December, 2015. Consolidated NAV per share was Tk. 63.00 as of December 31, 2016 and Tk. 59.13 as of June 30, 2016.

SQURPHARMA 23-Jan-2017

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2017 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2016.

SQURPHARMA 17-Jan-2017

The Company has informed that it has disbursed the cash dividend warrants for the 15 months period ended on June 30, 2016 to the respective shareholders' mailing address.

SQURPHARMA 09-Jan-2017

The Company has informed that the Board of Directors has decided to establish a pharmaceuticals manufacturing subsidiary company in Nairobi, Kenya. The Initial estimated total project cost will be US$ 20.00 million. US$ 8.00 million of it will be financed by equity investment by the company for which Bangladesh Bank has given permission and the balance would be invested from loan. It is expected that the project would be completed by June 2019.

SQURPHARMA 27-Dec-2016

Credit Rating Information and Services Limited (CRISL) has rated the Company as "AAA" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2016, unaudited financials up to September 30, 2016 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

SQURPHARMA 19-Dec-2016

The Company has informed that it has credited the Bonus shares for the 15 months period ended on June 30, 2016 to the respective shareholders' BO accounts on December 19, 2016.

SQURPHARMA 14-Nov-2016

Trading of the shares of the Company will resume on 15.11.2016 after record date.

SQURPHARMA 14-Nov-2016

(Q1 Un-audited): Consolidated EPS was Tk. 3.89 for July-September, 2016 as against Tk. 3.18 for July-September, 2015; Consolidated NOCFPS was Tk. 5.67 for July-September, 2016 as against Tk. 4.03 for July-September, 2015. Consolidated NAV per share was Tk. 69.17 as of September 30, 2016 and Tk. 65.04 as of June 30, 2016.

SQURPHARMA 13-Nov-2016

Trading of the shares of the Company will remain suspended on record date i.e., 14.11.2016.

Previous Next page